Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart
- Inge Van de Walle
- Laura Bracke
- Heidi Gytz Olesen
- Tonke van Bragt
- Stéphanie Cadour
- Phillip De Decker
- Giorgia Ciurlia
- Erwin Pannecoucke
- Emma K. Persson
- Olivier Van de Steen
- Xinghong Leng
- Gregers Rom Andersen
- Domenica Gandini
- C. Erik Hack
2025-08-16